Shenzhen Hepalink Pharmaceutical Company Limited operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shenzhen Hepalink Pharmaceutical Company Limited with three other
companies in this sector in China:
Shandong Lukang Pharmaceutical
sales of 2.51 billion Chinese Renmimbi [US$363.86 million]
of which 67%
was Human Antibiotic),
PKU HealthCare Corp Ltd
(2.07 billion Chinese Renmimbi [US$300.63 million]
of which 86%
was Merchandise&Material Selling), and
Zhejiang Jianfeng Group Company Limited
(2.38 billion Chinese Renmimbi [US$345.49 million]
of which 45%
During the year ended December of 2016, sales at
Shenzhen Hepalink Pharmaceutical Company Limited were 2.26 billion Chinese Renmimbi (US$328.16 million).
decrease of 1.3%
versus 2015, when the company's sales were 2.29 billion Chinese Renmimbi.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Shenzhen Hepalink Pharmaceutical Company Limited had sales
of 2.49 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 69.7% decline
in Other Operating, from 1.21 million Chinese Renmimbi to 367,490.08 Chinese Renmimbi.
There were also decreases in sales in
Pharmaceutical Manufacturing (down 1.3% to 2.26 billion Chinese Renmimbi)